Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (28)

I-13Henning Schmidt

The “SBPOP Package”: Efficient Support for Model Based Drug Development – From Mechanistic Models to Complex Trial Simulation

Wednesday 10:05-11:40

I-17Catherine Sherwin

Dense Data – Methods to Handle Massive Data Sets without Compromise

Wednesday 10:05-11:40

I-20

A conditional repeated time-to-event analysis of onset and retention times of sildenafil erectile response

Wednesday 10:05-11:40

I-44Anne van Rongen

Population pharmacokinetic model characterising the influence of circadian rhythm on the pharmacokinetics of oral and intravenous midazolam in healthy volunteers

Wednesday 10:05-11:40

I-60Klintean Wunnapuk

Population analysis of paraquat toxicokinetics in poisoning patients

Wednesday 10:05-11:40

II-10Martin Fink

Animal Health Modeling & Simulation Society (AHM&S): A new society promoting model-based approaches for a better integration and understanding of quantitative pharmacology in Veterinary Sciences

Wednesday 14:50-16:20

II-11Sylvain Fouliard

Semi-mechanistic population PKPD modelling of a surrogate biomarker

Wednesday 14:50-16:20

II-13

: Introducing DDMoRe’s framework within an existing enterprise modelling and simulation environment.

Wednesday 14:50-16:20

II-18Peter Gennemark

Incorporating model structure uncertainty in model-based drug discovery

Wednesday 14:50-16:20

II-28José David Gómez-Mantilla

Tailor-made dissolution profile comparisons using in vitro-in vivo correlation models.

Wednesday 14:50-16:20

II-32Bruce Green

Clinical Application of a K-PD Warfarin Model for Bayesian Dose Individualisation in Primary Care

Wednesday 14:50-16:20

II-45Lorenzo Ridolfi

Predictive Modelling Environment – Infrastructure and functionality for pharmacometric activities in R&D

Wednesday 14:50-16:20

II-53Niclas Jonsson

Population PKPD analysis of weekly pain scores after intravenously administered tanezumab, based on pooled Phase 3 data in patients with osteoarthritis of the knee or hip

Wednesday 14:50-16:20

II-64Julia Korell

Gaining insight into red blood cell destruction mechanisms using a previously developed semi-mechanistic model

Wednesday 14:50-16:20

III-14Yan Li

Modeling and Simulation to Probe the Likely Difference in Pharmacokinetic Disposition of R- and S-Enantiomers Justifying the Development of Racemate Pomalidomide

Thursday 10:05-11:35

III-15Lia Liefaard

Predicting levels of pharmacological response in long-term patient trials based on short-term dosing PK and biomarker data from healthy subjects

Thursday 10:05-11:35

III-16Karl-Heinz Liesenfeld

Pharmacometric Characterization of the Elimination of Dabigatran by Haemodialysis

Thursday 10:05-11:35

III-24

Using modelling and simulation to evaluate potential drug repositioning to a new therapy area

Thursday 10:05-11:35

III-28Hafedh Marouani

Dosage regimen individualization of the once-daily amikacin treatment by using kinetics nomograms.

Thursday 10:05-11:35

III-30María Isabel Mas Fuster

Stochastic Simulations Assist to Select the Intravenous Digoxin Dosing Protocol in Elderly Patients in Acute Atrial Fibrillation

Thursday 10:05-11:35

III-45Tram Nguyen

Influence of a priori information, designs and undetectable data on individual parameters estimation and prediction of hepatitis C treatment outcome

Thursday 10:05-11:35

III-51Fredrik Öhrn

Longitudinal Modelling of FEV1 Effect of Bronchodilators

Thursday 10:05-11:35

IV-12Ioanna Athanasiadou

Simulation of the effect of hyperhydration on urine levels of recombinant human erythropoietin from a doping control point of view

Thursday 14:55-16:20

IV-18Marcus Björnsson

Effect on bias in EC50 when using interval censoring or exact dropout times in the presence of informative dropout

Thursday 14:55-16:20

IV-33Theresa Cain

Prediction of Rosiglitazone compliance from last sampling information using Population based PBPK modelling and Bayes theorem: Comparison of prior distributions for compliance.

Thursday 14:55-16:20

IV-38Phylinda Chan

Industry Experience in Establishing a Population Pharmacokinetic Analysis Guidance

Thursday 14:55-16:20

IV-43Nianhang Chen

Comparison of Two Parallel Computing Methods (FPI versus MPI) in NONMEM 7.2 on complex popPK and popPK/PD Models

Thursday 14:55-16:20

IV-44Marylore Chenel

Population Pharmacokinetic Modelling to Detect Potential Drug Interaction Using Sparse Sampling Data

Thursday 14:55-16:20